Analysts Set Avidity Biosciences, Inc. (NASDAQ:RNA) Price Ta

Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) has received a consensus rating of “Buy” from the six research firms that are covering the firm, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective […]

Related Keywords

, Charles Schwab Investment Management Inc , Wells Fargo Company , Avidity Biosciences Inc , Nasdaq , Avidity Biosciences Company Profile , Metlife Investment Management , Dimensional Fund Advisors , Vanguard Group Inc , Avidity Biosciences , Get Free Report , Marketbeat Ratings , Wells Fargo , Life Investment Management , Fund Advisors , Charles Schwab Investment Management , Schwab Investment Management , Get Free , Avidity Biosciences Daily , Nasdaq Rna , Rna , Medical , Ratings , Consensus ,